Skip to main content

Table 1 Eligibility criteria [4]

From: Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide

Inclusion criteria Exclusion criteria
Age > 18 years Previous adverse reaction to any of the study medications
Advanced cancer Australia-modified Karnofsky Performance Score < 30 at study entry
Disease-modifying therapy (surgery, chemotherapy, radiotherapy, hormone therapy, biological/targeted therapies) is unlikely to change the bowel obstruction. Participated in a clinical study of a new chemical entity < 1 month before study entry
Presents with clinically confirmed bowel obstruction with vomiting that precipitates change in clinical care or a hospital admission. Calculated creatinine clearance < 10 mL/minute
A partial or complete bowel obstruction for which immediate surgery is not indicated (confirmed by two consultant-level medical practitioners). Clinically significant cirrhosis (documented)
Able to complete assessments and comply with the study procedures Feeding or venting gastrostomy or jejunostomy
Able to give fully informed written consent  
Not currently on octreotide